Search Results

Two-Year LEADERS FREE Data Presented for BioSensors' BioFreedom Drug-Coated Stent

October 30, 2016—The 2-year results from LEADERS FREE were reported at TCT 2016, the 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, DC, and simultaneously published online by Philippe Garot, MD, et al in the Journal of the American College of Cardiology.

European STRENGTH Trial Will Evaluate Long-Term Impact of RenalGuard Therapy in Patients at High Risk for CI-AKI

January 26, 2016—RenalGuard Solutions, Inc. announced that the STRENGTH trial will begin later this year.

FEops HeartGuide for Planning LAAO Procedures Evaluated in the PREDICT-LAA Trial

September 17, 2022—FEops, a Belgium-based developer of the HeartGuide cloud-based procedure planning solution, announced that data from the PREDICT-LAA trial demonstrated that left atrial appendage occlusion (LAAO) procedures planned via HeartGuide resulted in significantly improved procedural efficiency and outcomes.

FEops HeartGuide for LAAC Procedures Studied in Published PREDICT-LAA Trial

February 24, 2023—FEops, a Belgium-based developer of the HeartGuide cloud-based procedure planning solution, announced the publication of the PREDICT-LAA study showing that left atrial appendage closure (LAAC) procedures planned by means of HeartGuide resulted in significant improvement of procedural efficiency and outcomes.

Conformal Medical’s Pivotal Trial of CLAAS AcuForm LAAO Device Begins European Enrollment

October 15, 2025—Conformal Medical Inc. announced the initiation of European Union patient enrollment in the CONFORM pivotal trial, which is evaluating the safety and efficacy of the company’s CLAAS AcuForm left atrial appendage occlusion (LAAO) device.

PRO-TAVI: PCI Deferral Noninferior to PCI Before TAVR at 1 Year

April 1, 2026—Deferring percutaneous coronary intervention (PCI) until after transcatheter aortic valve replacement (TAVR) resulted in similar 1-year clinical outcomes compared with performing PCI before TAVR in older patients with severe aortic stenosis (AS) and coronary artery disease (CAD), according to results of the PRO-TAVI trial presented at ACC.26 and simultaneously published in The Lancet.